Joseph Vayalumkal
Alberta Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joseph Vayalumkal.
CJEM | 2007
Joseph Vayalumkal; Heather Whittingham; Otto G. Vanderkooi; Thomas E. Stewart; Donald E. Low; Michael R. Mulvey; Allison McGeer
We report a case of fatal necrotizing pneumonia and sepsis caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in an otherwise well, 48-year-old Canadian man with type 2 diabetes mellitus who had travelled to Texas. Despite therapy that included intravenous antibiotics, intravenous immune globulin and other supportive measures, the patient succumbed to his illness. Recently, CA-MRSA pneumonia has been reported in several countries. The virulence of this organism may in part be related to its ability to produce toxins, such as Panton-Valentine leukocidin. As rates of CA-MRSA increase worldwide, physicians should be aware of the potential for MRSA to cause life-threatening infections in patients presenting to Canadian emergency departments (EDs). Necrotizing pneumonia caused by MRSA must be considered in the differential diagnosis of acute, severe respiratory illness. Early recognition of this syndrome in the ED may help physicians initiate appropriate antibiotic therapy in a timely manner.
Pediatric Drugs | 2006
Joseph Vayalumkal; Tajdin Jadavji
Skin and soft tissue infections in children are an important cause for hospitalization. A thorough history and physical examination can provide clues to the pathogens involved. Collection of purulent discharge from lesions should be completed prior to initiating antimicrobial therapy, and results of bacteriologic studies (Gram stain and culture) should guide therapeutic decisions.The main pathogens involved in these infections are Staphylococcus aureus and group A β-hemolytic streptococci, but enteric organisms also play a role especially in nosocomial infections. Increasing antibacterial resistance is becoming a major problem in the treatment of these infections worldwide. Specifically, the rise of methicillin-resistant S. aureus and glycopeptide-resistant S. aureus pose challenges for the future.Infections of the skin and soft tissues can be broadly classified based on the extent of tissue involvement. Superficial infections such as erysipelas, cellulitis, bullous impetigo, bite infections, and periorbital cellulitis may require hospitalization and parenteral antibacterials. Deeper infections such as orbital cellulitis, necrotizing fasciitis, and pyomyositis require surgical intervention as well as parenteral antibacterial therapy. Surgery plays a key role in the treatment of abscesses and for the debridement of necrotic tissue in deep infections. Intravenous immunoglobulin, as an adjunctive therapy, can be helpful in treating necrotizing fasciitis.For most infections an antistaphylococcal β-lactam antibacterial is first-line therapy. Third-generation cephalosporins and β-lactam/β-lactamase inhibitor antibacterials as well as clindamycin or metronidazole are often required to provide broad-spectrum coverage for polymicrobial infections.Special populations, such as immunocompromised children, those with an allergy to penicillins, and those that acquire infections in hospitals, require specific antibacterial strategies. These usually involve broader antimicrobial coverage with increased Gram-negative (including antipseudomonal) and anerobic coverage. In patients with a true allergy to penicillins, clindamycin and vancomycin play an important role in treating Gram-positive infections. Newer antibacterial agents, such as linezolid and quinupristin/dalfopristin, are increasingly being studied in children for the treatment of skin and soft tissue infections. These agents hold promise for the future especially in the treatment of highly resistant, Gram-positive organisms such as methicillin-resistant S. aureus, vancomycin-resistant S. aureus, and vancomycin-resistant enterococci.
Infection Control and Hospital Epidemiology | 2009
Joseph Vayalumkal; Denise Gravel; Dorothy Moore; Anne Matlow
OBJECTIVE To determine the rates of healthcare-acquired febrile respiratory infection (HA-FRI) in Canadian pediatric hospitals and to determine the vaccination status of patients with healthcare-acquired respiratory syncytial virus (RSV) infection, influenza, or pneumococcal infection who were also eligible for immunoprophylaxis. METHODS Prospective surveillance was conducted in 8 hospitals from January 1 to April 30, 2005. All hospitalized patients less than 18 years of age were eligible, except for patients housed in standard newborn nurseries or psychiatric units. Infection control professionals reviewed laboratory reports, conducted ward rounds, and reviewed medical records to identify case patients. Descriptive analyses were completed, as well. RESULTS A total of 96 case patients were identified; 52 (54%) were male, and 48 (50%) were aged 1 year or less. Seventy-two patients (75%) had chronic medical conditions. Respiratory viruses accounted for 72 (71%) of 101 pathogens identified, and RSV was the virus most frequently identified. Of these 96 patients, 9 (9%) died, and 3 (3%) of the deaths were related to the patients HA-FRI. The mean incidence rate was 0.97 infections/1,000 patient-days (range, 0.29-1.50 infections/1,000 patient-days). Only 2 (15%) of 13 influenza vaccine-eligible children who acquired influenza while hospitalized were reported to have been vaccinated, but influenza vaccination status was unknown for most children. However, 4 (80%) of 5 RSV prophylaxis-eligible children who had healthcare-acquired RSV infection had received immunoprophylaxis with anti-RSV monoclonal antibody. CONCLUSIONS HA-FRI is mainly caused by viruses such as RSV, and it primarily affects children under 1 year of age and those with chronic medical conditions.
American Journal of Infection Control | 2012
Leslie Forrester; Jun Chen Collet; Robyn Mitchell; Linda Pelude; Elizabeth Henderson; Joseph Vayalumkal; Stéphanie Leduc; Saeed Ghahreman; Christine Weir; Denise Gravel
BACKGROUND The Canadian Nosocomial Infection Surveillance Program (CNISP) has conducted surveillance for incident cases of methicillin-resistant Staphylococcus aureus (MRSA) in sentinel hospitals since 1995. In 2007, a reliability audit of the 2005 data was conducted. METHODS In 2005, 5,652 cases were submitted to the CNISP from 43 hospitals. A proportional sample of submitted forms (up to 25) from each site were randomly selected. Stratified random sampling was used to obtain the comparison data. The original data were compared with the reabstracted data for congruence on 7 preselected variables. RESULTS Reabstracted data were received from 30 out of 43 hospitals (70%), providing 443 of the 598 case forms requested (74%). Of these, 397 (90%) had matching case identification numbers. Overall, the percentage of discordant responses was 7.0%, ranging from 3.5% for sex and up to 23.7% for less well-defined variables (eg, where MRSA was acquired). CONCLUSION Our findings suggest that, in general, the 2005 MRSA data are reliable. However to improve reliability a data quality framework with quality assurance practices, including ongoing auditing should be integrated into the CNISPs surveillance programs. Providing training to data collectors and standard definitions with practical examples may help to improve data quality, especially for those variables that require clinical judgment.
Infection Control and Hospital Epidemiology | 2014
Nipunie Rajapakse; Joseph Vayalumkal; Debbie Lam-Li; Craig Pearce; Gwynne Rees; Linda N. Kamhuka; Gisele Peirano; Corrinne Pidhorney; Donna Ledgerwood; Nancy Alfieri; Karen Myrthu Hope; Dan Gregson; Johann D. D. Pitout; Thomas J. Louie; John Conly
Nipunie Rajapakse1, Joseph Vayalumkal1,2, Debbie Lam-Li2, Craig Pearce2, Gwynne Rees2, Linda Kamhuka2, Gisele Peirano3, Corrinne Pidhorney2, Donna Ledgerwood2, Nancy Alfieri2, Karen Hope2, Dan Gregson3,4, Johann Pitout3, Thomas Louie 2,4, John Conly2,3,4 1Department of Pediatrics, Alberta Children’s Hospital, Calgary, Alberta, Canada 2Infec=on Preven=on and Control, Alberta Health Services – Calgary Zone, Calgary, Alberta, Canada 3Calgary Lab Services, Calgary, Alberta, Canada 4Department of Medicine, University of Calgary, Calgary, Alberta, Canada
Paediatrics and Child Health | 2017
Kevin Mitchell; Joseph Vayalumkal
Background Sickness presenteeism is defined as the act of attending ones job despite ill-health. Recently, physicians and other health care workers have become the focus of sickness presenteeism research, because presenteeism in this population can put patients at risk of infection. There are currently no data on this topic among physicians in Canada. The aim of this study was to investigate sickness presenteeism in paediatric resident physicians in Canada. Methods We conducted an anonymous, online, cross-sectional survey study in which all paediatric residents in Canada were eligible. Outcomes of interest included prevalences of sickness presenteeism, sickness during the study period and voluntary self-appointed personal protective equipment use when engaging in sickness presenteeism. Results Response rate was 56.5% (N=323). During the previous 2 months, 61% (95% confidence interval [CI] 55.7 to 66.3) of respondents reported having experienced an illness and 59% (95% CI 53.7 to 64.5) of respondents had come to work sick. Of those who reported becoming ill during the study period, 97.0% (95% CI 94.6 to 99.4) reported coming to work while sick. There was no difference in prevalence when comparing across post-graduate year training levels. Extra personal protective equipment was used by 86% (95% CI 82.1 to 91.7) when engaging in sickness presenteeism. Conclusion Sickness presenteeism is a common phenomenon among paediatric resident physicians. Our results should influence residents and supervising staff physicians to encourage appropriate self-care at home, rather than presenteeism.
Canadian Journal of Infectious Diseases & Medical Microbiology | 2015
Bruce Dalton; Sandra J MacTavish; Lauren C. Bresee; Nipunie Rajapakse; Otto G. Vanderkooi; Joseph Vayalumkal; John Conly
Proper assessment of antimicrobial use in pediatric populations is challenging due to the common metric unit, the defined daily dose. In this study, the authors quantified pediatric antimicrobial use using days of therapy per 100 patient days, a value that is numerically comparable with adult antibiotic use. An overview of systemic antibacterial and antifungal use according to ward at the Alberta Children’s Hospital (Calgary, Alberta) is also provided. The authors suggest that their data act as a benchmark for future reference in other antimicrobial studies and pediatric institutions.
Journal of Antimicrobial Chemotherapy | 2018
David Boyd; Laura Mataseje; Linda Pelude; Robyn Mitchell; Elizabeth Bryce; Diane Roscoe; Joanne Embree; Kevin Katz; Pamela Kibsey; Christian Lavallée; Andrew E. Simor; Geoffrey Taylor; Nathalie Turgeon; Joanne M. Langley; Kanchana Amaratunga; Michael R. Mulvey; Alice Wong; Allison McGeer; Bonita E. Lee; Charles Frenette; Chelsea Ellis; Dominik Mertz; Elizabeth Henderson; Gregory German; Ian Davis; Janice de Heer; Jessica Minion; Jocelyn A. Srigley; John M. Embil; Joseph Vayalumkal
Objectives Globally there is an increased prevalence of carbapenem-resistant Acinetobacter spp. (CRAs) and carbapenemase-producing Acinetobacter spp. (CPAs) in the hospital setting. This increase prompted the Canadian Nosocomial Infection Surveillance Program (CNISP) to conduct surveillance of CRA colonizations and infections identified from patients in CNISP-participating hospitals between 2010 and 2016. Methods Participating acute care facilities across Canada submitted CRAs from 1 January 2010 to 31 December 2016. Patient data were collected from medical records using a standardized questionnaire. WGS was conducted on all CRAs and data underwent single nucleotide variant analysis, resistance gene detection and MLST. Results The 7 year incidence rate of CRA was 0.02 per 10 000 patient days and 0.015 per 1000 admissions, with no significant increase observed over the surveillance period (P > 0.73). Ninety-four CRA isolates were collected from 58 hospitals, of which 93 (98.9%) were CPA. Carbapenemase OXA-235 group (48.4%) was the most common due to two separate clusters, followed by the OXA-23 group (41.9%). Patients with a travel history were associated with 38.8% of CRA cases. The all-cause 30 day mortality rate for infected cases was 24.4 per 100 CRA cases. Colistin was the most active antimicrobial agent (95.8% susceptibility). Conclusions CRA remains uncommon in Canadian hospitals and the incidence did not increase from 2010 to 2016. Almost half of the cases were from two clusters harbouring OXA-235-group enzymes. Previous medical treatment during travel outside of Canada was common.
American Journal of Infection Control | 2007
Joseph Vayalumkal; Laurie Streitenberger; Rick Wray; Carol Goldman; Renee Freeman; Steven J. Drews; Anne Matlow
CJEM | 2012
Joseph Vayalumkal; Kathryn N. Suh; Baldwin Toye; Karamchand Ramotar; Raphael Saginur; Virginia Roth